Cargando…

Success of Crizotinib Combined with Whole-Brain Radiotherapy for Brain Metastases in a Patient with Anaplastic Lymphoma Kinase Rearrangement-Positive Non-Small-Cell Lung Cancer

Although crizotinib shows marked antitumor activity in anaplastic lymphoma kinase (ALK) rearrangement-positive non-small-cell lung cancer (NSCLC) patients, all treated patients ultimately develop resistance to this drug. Isolated central nervous system failure without progression at extracranial sit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okawa, Sachi, Shibayama, Takuo, Shimonishi, Atsushi, Nishimura, Jun, Ozeki, Taichi, Takada, Kenji, Kayatani, Hiroe, Minami, Daisuke, Sato, Ken, Fujiwara, Keiichi, Yonei, Toshiro, Sato, Toshio, Suno, Manabu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323405/ https://www.ncbi.nlm.nih.gov/pubmed/30627092 http://dx.doi.org/10.1159/000492150

Ejemplares similares

Bilateral Testicular Metastases from Lung Adenocarcinoma Showing an Objective Response to Nivolumab: A Case Report and Review of the Literature
por: Ozeki, Taichi, et al.
Publicado: (2019)

Comparing the Clinical Performance of the New 19-G ViziShot FLEX and 21- or 22-G ViziShot 2 Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Needles
por: Minami, Daisuke, et al.
Publicado: (2018)

Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer
por: Okawa, Sachi, et al.
Publicado: (2019)

Rapidly Progressive Acute Kidney Injury Associated with Nivolumab Treatment
por: Okawa, Sachi, et al.
Publicado: (2020)

Rapidly Progressive Multiple Cavity Formation in Necrotizing Pneumonia Caused by Community-acquired Methicillin-resistant Staphylococcus aureus Positive for the Panton-Valentine Leucocidin Gene
por: Takigawa, Yuki, et al.
Publicado: (2018)

Effectiveness of benralizumab for allergic and eosinophilic predominant asthma following negative initial results with omalizumab
por: Minami, Daisuke, et al.
Publicado: (2018)

Transoesophageal ultrasound‐guided bronchoscopic aspiration of a superior mediastinal tumour using the BF‐UC290F instrument
por: Minami, Daisuke, et al.
Publicado: (2019)

Usefulness of Bronchial Thermoplasty for Patients with a Deteriorating Lung Function
por: Minami, Daisuke, et al.
Publicado: (2017)

Multiple Mucosa-associated Lymphoid Tissue Lymphoma of the Trachea
por: Minami, Daisuke, et al.
Publicado: (2017)

nab-Paclitaxel in Combination with Carboplatin for a Previously Treated Thymic Carcinoma
por: Makimoto, Go, et al.
Publicado: (2014)

Anaplastic lymphoma kinase (ALK)-rearranged pulmonary pleomorphic carcinoma successfully treated with crizotinib
por: Lin, Liping, et al.
Publicado: (2018)

Successful Crizotinib Rechallenge after Crizotinib-Induced Organizing Pneumonia in Anaplastic Lymphoma Kinase-Rearranged Non-Small Cell Lung Cancer
por: Asai, Nobuhiro, et al.
Publicado: (2014)

Correlation of plasma crizotinib trough concentration with adverse events in patients with anaplastic lymphoma kinase positive non-small-cell lung cancer
por: Kurata, Yasuko, et al.
Publicado: (2015)

The impact of baseline brain metastases on clinical benefits and progression patterns after first-line crizotinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer
por: Chen, Yuqi, et al.
Publicado: (2021)

Control of brain metastases with alectinib in anaplastic lymphoma kinase‐rearranged lung cancer
por: Kwok, Wang Chun, et al.
Publicado: (2017)

Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer
por: Guo, Liting, et al.
Publicado: (2015)

Good Tolerance to Full-Dose Crizotinib in a Patient with Anaplastic Lymphoma Receptor Tyrosine Kinase-Rearranged Lung Adenocarcinoma and Preexisting Renal Impairment
por: Rosoux, Adeline, et al.
Publicado: (2017)

Successful Desensitization with Crizotinib after Crizotinib-induced Liver Injury in ROS1-rearranged Lung Adenocarcinoma
por: Ota, Takayo, et al.
Publicado: (2019)

Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma
por: Xu, Wendan, et al.
Publicado: (2018)

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib
por: Schneider, Jaime L., et al.
Publicado: (2022)

Concomitant expression of exon 19 mutation epidermal growth factor receptor and anaplastic lymphoma kinase gene rearrangement in metastatic adenocarcinoma lung responsive to crizotinib
por: Purkayastha, Abhishek, et al.
Publicado: (2018)

Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report
por: Kothari, Shalin, et al.
Publicado: (2016)

Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond
por: Ou, Sai-Hong Ignatius
Publicado: (2011)

Anaplastic multiple myeloma with MYC rearrangement
por: Ichikawa, Satoshi, et al.
Publicado: (2021)

Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer
por: Kuriyama, Yuka, et al.
Publicado: (2013)

Hemorrhagic Brain Metastases in a Patient with Anaplastic Lymphoma Kinase (ALK)-Rearranged Invasive Mucinous Adenocarcinoma of the Lung
por: Shi, Mingxia, et al.
Publicado: (2018)

Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy
por: Ryu, Woo Kyung, et al.
Publicado: (2022)

Successful Treatment with Low-dose Crizotinib in a Patient with ROS1-rearranged Lung Cancer Who Developed Crizotinib-induced Heart Failure
por: Hashimoto, Takahiko, et al.
Publicado: (2022)

Clinical data from the real world: efficacy of Crizotinib in Chinese patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases
por: Xing, Puyuan, et al.
Publicado: (2016)

Entrectinib for ROS1‐rearranged non‐small cell lung cancer after crizotinib‐induced interstitial lung disease: A case report
por: Tanimura, Mai, et al.
Publicado: (2021)

Mechanism of bacterial gene rearrangement: SprA-catalyzed precise DNA recombination and its directionality control by SprB ensure the gene rearrangement and stable expression of spsM during sporulation in Bacillus subtilis
por: Abe, Kimihiro, et al.
Publicado: (2017)

Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
por: Mitou, Géraldine, et al.
Publicado: (2015)

Combination therapy with crizotinib and vinblastine for relapsed or refractory pediatric ALK-positive anaplastic large cell lymphoma
por: Knörr, Fabian, et al.
Publicado: (2022)

Crizotinib, an Effective Agent in ROS1-Rearranged Adenocarcinoma of Lungs: A Case Report
por: Joshua, Julie Mariam, et al.
Publicado: (2018)

Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
por: Zhang, Limin, et al.
Publicado: (2016)

Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021)

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
por: Mansfield, A. S., et al.
Publicado: (2022)

Multiple Brain Metastases in a Patient with ROS1 Fusion-Positive Lung Adenocarcinoma as a Disease Flare due to Crizotinib Cessation Caused by Disseminated Aseptic Inflammation from Crizotinib-Associated Renal Cysts: A Case Report
por: Amano, Yosuke, et al.
Publicado: (2022)

Successful Treatment with Benralizumab for Allergic Bronchopulmonary Aspergillosis That Developed after Disastrous Heavy Rainfall in Western Japan
por: Matsuura, Hiroaki, et al.
Publicado: (2020)

A CT‐based radiomics model to predict subsequent brain metastasis in patients with ALK‐rearranged non–small cell lung cancer undergoing crizotinib treatment
por: Jiang, Yongluo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_oiga2onplno3ptq2t8kjigefs2